Results 171 to 180 of about 6,422,021 (278)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Plasma Hormone and Metabolomics Identifies Metabolic Pathways Associated with Growth Rate of Dezhou Donkeys. [PDF]

Animals (Basel)
Wang L, Li T, Ma Q, Qu H, Wang C, Liu W, Chai W.   +6 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Improved maximum growth rate prediction from microbial genomes by integrating phylogenetic information. [PDF]

Nat Commun
Xu L, Zakem E, Weissman JL.
europepmc   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Growth-rate distributions of gut microbiota time series. [PDF]

Sci Rep
Brigatti E, Azaele S.
europepmc   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Seedling growth rate and root traits in the maize Nested Association Mapping (NAM) panel. [PDF]

BMC Res Notes
Montoya-Pimolwatana M, McClellan Maaz T, Kantar M, Muszynski M, Mileyko Y, Prasadh R, Dhungana I, Kiehl K, Ana AH, Nguyen A, Tausaga A, Godfrey A, Nitta AK, Tugade B, JadenYamagata-Santos D, Swantek E, Morrell ES, Kalaiwaa G, Juan GL, Larsen G, Ching IK, Mikasobe-Kealiinohomoku J, Araszewski J, Averion JCM, Strachan K, Torres KA, Botanes K, Wilkes KC, Rigge L, Lo M, Carr N, Brenner N, Johnson O, Malasarte RAB, Noland R, Naldini S, Santos SA, Pierce T, Halpern U, Miguel ZGP, Gan Z, Nguyen NH.   +41 more
europepmc   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Perfusion-derived metrics to calculate cerebral infarct growth rate, "ultrafast progressor" phenotype, and neuroprotection. [PDF]

J Cereb Blood Flow Metab
Pensato U, Ospel JM.
europepmc   +1 more source